Regulation of secretion by vasoactive intestinal peptide in isolated perfused rat submandibular glands.
The isolated, perfused gland was used to examine the regulation of saliva volume and protein content by vasoactive intestinal peptide (VIP). In the absence of other secretagogues, VIP produced a modest, sustained saliva flow with a biphasic dose-response curve in which saliva volume was greatest at 1 nM VIP (28.5 +/- 3.8 microliters in the first 5 min, n = 4) but reduced at lower and higher concentrations. The protein concentration in saliva released in response to VIP (0.86 +/- 0.13 micrograms/microliters) was substantially higher than with 30 nM acetylcholine (0.06 +/- 0.02 micrograms/microliters) or 1 nM substance P (0.30 +/- 0.05 micrograms/microliters). During the first 5 min of stimulation, VIP and substance P were synergistic in terms of volume and protein content whereas inclusion of VIP did not increase acetylcholine-stimulated flow in the first 5 min but produced a higher sustained flow over the next hour. After stimulation with acetylcholine, subsequent addition of VIP transiently enhanced saliva volume and protein content in a monophasic, dose-dependent manner with effects at 1 pM VIP and higher. The responses were different for VIP compared with other cAMP-mobilizing agents and the involvement of multiple VIP receptor subtypes was suggested from experiments in which a VIP antagonist blocked the VIP enhancement of saliva volume but not the increase in protein.
Turner
J T
JT
Department of Pharmacology, School of Medicine, University of Missouri-Columbia 65212.
Camden
J M
JM
D000109:Acetylcholine / Q000008:administration & dosage / Q000494:pharmacology*; D000527:Alprostadil / Q000494:pharmacology; D000818:Animals; D010478:Chemotherapy, Cancer, Regional Perfusion; D005576:Colforsin / Q000494:pharmacology; D000242:Cyclic AMP / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D010446:Peptide Fragments / Q000037:antagonists & inhibitors / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D012463:Saliva / Q000737:chemistry / Q000187:drug effects* / Q000378:metabolism; D012471:Salivary Proteins and Peptides / Q000032:analysis*; D012636:Secretory Rate / Q000187:drug effects; D013363:Submandibular Gland / Q000187:drug effects* / Q000378:metabolism; D013373:Substance P / Q000008:administration & dosage / Q000494:pharmacology*; D014660:Vasoactive Intestinal Peptide / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*
D010446:Peptide Fragments; D012471:Salivary Proteins and Peptides; D005576:Colforsin; D013373:Substance P; D014660:Vasoactive Intestinal Peptide; C047945:vasoactive intestinal peptide (10-28); D000242:Cyclic AMP; D000527:Alprostadil; D007545:Isoproterenol; D000109:Acetylcholine